Myelodysplastic Syndromes
📧 Sign up to get email alerts when something new happens for Myelodysplastic Syndromes.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2017-02-23Clinical Trial Update: Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload [Phase 4]
Novartis-sponsored Phase 4 trial assessing heart and liver iron load by MRI in patients with transfusion-related iron overload; the study st…
-
CLINICAL_TRIALS trial_result · 2017-02-20Clinical Trial Update: Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia [Phase 1]
Phase 1 trial evaluating low-dose total-body irradiation and fludarabine phosphate followed by an unrelated donor stem cell transplant in pa…
-
CLINICAL_TRIALS trial_result · 2017-02-15Clinical Trial Update: Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome [Phase 2]
Phase 2 trial evaluating the combination of tosedostat with cytarabine or decitabine in adults with newly diagnosed acute myeloid leukemia o…
-
CLINICAL_TRIALS trial_result · 2017-02-15Clinical Trial Update: Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/2 study evaluating therapeutic allogeneic lymphocytes with aldesleukin for high-risk or recur…
-
CLINICAL_TRIALS trial_result · 2017-02-10Clinical Trial Update: Autologous Cytokine-induced Killer Cell Adoptive Immunotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome [Phase 1, Phase 2]
Phase 1/2 trial evaluating autologous cytokine-induced killer cell adoptive immunotherapy for acute myeloid leukemia and myelodysplastic syn…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2017-02-07Clinical Trial Update: Efficacy and Safety of Ultra Small Dose Decitabine for the Lower Risk MDS Patients With Transfusion Dependent [Phase 2]
This Phase 2 clinical trial update evaluates the efficacy and safety of ultra-small-dose decitabine in lower-risk, transfusion-dependent mye…
-
CLINICAL_TRIALS trial_result · 2017-02-07Clinical Trial Update: Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia [Phase 1]
Phase 1 pilot trial of lenalidomide in adult Diamond-Blackfan anemia patients with transfusion-dependent anemia. The study was terminated an…
-
CLINICAL_TRIALS trial_result · 2017-02-06Clinical Trial Update: Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox. [Phase 2]
A Phase II trial in higher-risk myelodysplastic syndromes evaluating azacitidine with or without deferasirox has been terminated; results ha…
-
CLINICAL_TRIALS trial_result · 2017-02-03Clinical Trial Update: Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome [NA]
This clinical trial update indicates the Lactobacillus probiotic study intended to prevent infection in patients undergoing donor stem cell …
-
FDA approval · 2017-01-30FDA Approved: VIDAZA — Supplemental Application (Celgene Corporation)
The FDA approved a supplemental application for Vidaza (azacitidine) submitted by Celgene Corporation.
-
CLINICAL_TRIALS trial_result · 2017-01-25Clinical Trial Update: LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS) [Phase 2]
A Phase 2 trial evaluated LBH589 (panobinostat) alone or with erythropoietin-stimulating agents in low- or Int-1 risk myelodysplastic syndro…
-
CLINICAL_TRIALS trial_result · 2016-12-15Clinical Trial Update: Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer [Phase 1]
Phase 1 study evaluating alemtuzumab with combination chemotherapy followed by donor lymphocyte infusion in patients undergoing donor stem c…
-
CLINICAL_TRIALS trial_result · 2016-12-12Clinical Trial Update: Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study [Phase 1]
This report provides long-term safety results from an extension Phase 1 study of SyB C-1101 in patients with recurrent/relapsed or refractor…
-
CLINICAL_TRIALS trial_result · 2016-12-08Clinical Trial Update: Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder [Phase 3]
Phase 3 trial evaluating cyclosporine eye drops to prevent eye graft-versus-host disease in patients after donor stem cell transplant for he…
-
CLINICAL_TRIALS trial_result · 2016-11-22Clinical Trial Update: Safety, Tolerability, and Efficacy of Deferasirox in MDS [Phase 3]
Phase 3 trial evaluating safety, tolerability, and efficacy of deferasirox in myelodysplastic syndromes, focusing on iron chelation in patie…
-
CLINICAL_TRIALS trial_result · 2016-11-08Clinical Trial Update: Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms [Phase 2]
Phase 2 clinical trial update studying molecular and genetic abnormalities in patients with myeloid neoplasms, including Acute myeloid leuke…
-
CLINICAL_TRIALS trial_result · 2016-11-08Clinical Trial Update: Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality. [Phase 2]
A completed Phase 2 trial evaluating lenalidomide in patients with low- and intermediate-1 risk myelodysplastic syndromes without chromosome…
-
CLINICAL_TRIALS trial_result · 2016-11-08Clinical Trial Update: GFM-Acadesine: A Phase I-II Trial of Acadesine [Phase 1, Phase 2]
A Phase 1/2 trial evaluating acadesine (GFM-Acadesine) for myelodysplastic syndromes has been terminated.
-
CLINICAL_TRIALS trial_result · 2016-10-13Clinical Trial Update: LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) [Phase 1, Phase 2]
This Phase 1/2 clinical trial evaluated the combination of LBH589 (panobinostat) and decitabine in patients with acute myeloid leukemia or m…
-
FDA approval · 2016-09-29FDA Approved: AZACITIDINE — Original Application (Fresenius Kabi USA, LLC)
FDA approved Fresenius Kabi USA, LLC's azacitidine injection as an original application (ANDA) for a generic version. It is approved for the…
-
CLINICAL_TRIALS trial_result · 2016-09-21Clinical Trial Update: High-Tc Susceptometer to Monitor Transfusional Iron Overload
Clinical trial update reporting that the study evaluating a High-Tc Susceptometer to monitor transfusional iron overload has completed, in p…
-
CLINICAL_TRIALS withdrawal · 2016-09-20Clinical Trial Update: A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) [Phase 2]
A Phase 2 trial of epoetin alfa in anemic patients with low- or intermediate-1 risk myelodysplastic syndromes has been withdrawn from develo…
-
CLINICAL_TRIALS research · 2016-09-09Clinical Trial Update: Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS [Phase 2, Phase 3]
An update on a Phase 2/Phase 3 trial evaluating CHG regimen versus Decitabine for higher-risk myelodysplastic syndromes; no results are prov…
-
CLINICAL_TRIALS trial_result · 2016-08-31Clinical Trial Update: Phase I Study Evaluating TXA127 in Low/Intermediate-1 Risk Myelodysplastic Syndrome and Thrombocytopenia [Phase 1]
A Phase I study of TXA127 in patients with low/intermediate-1 risk myelodysplastic syndromes and thrombocytopenia was terminated.
-
FDA approval · 2016-08-23FDA Approved: VIDAZA — Supplemental Application (Celgene Corporation)
The FDA approved a supplemental application for Vidaza (azacitidine) submitted by Celgene Corporation, updating/adding to the product's labe…